C. Russ

发表

Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES

N. Benowitz, R. West, A. Krishen, 2018, Addiction.

Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control.

D. Bertrand, R. Hurst, C. Russ, 2014, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA

C. Russ, M. Ferri, I. Hernandez, 2021, American Journal of Cardiovascular Drugs.

A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation.

L. Mantovani, R. Lopes, A. Earley, 2020, International journal of cardiology.

Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States

C. Russ, A. Nadkarni, O. Dina, 2018, Advances in Therapy.

Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings

J. Kline, C. Russ, M. Ferri, 2020, Hospital practice.

Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline

S. Tonstad, J. Hughes, C. Russ, 2010, Drug safety.

Correction: Effects of Varenicline on Smoking Cessation in Adults With Stably Treated Current or Past Major Depression

S. Dubrava, R. Anthenelli, C. Russ, 2013, Annals of Internal Medicine.

Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials.

K. Zou, J. Hughes, A. Berg, 2013, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries

K. Fagerström, C. Russ, Hong-Jun Cho, 2010, Current medical research and opinion.

Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study

C. Russ, M. Ferri, G. Piazza, 2022, Journal of Thrombosis and Thrombolysis.

Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration

M. Turakhia, C. Russ, P. Hlavacek, 2021, Circulation. Cardiovascular quality and outcomes.

Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department

C. Russ, P. Hlavacek, Jay Lin, 2020, Hospital practice.

Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study

C. Russ, M. Ferri, G. Piazza, 2022, Journal of Thrombosis and Thrombolysis.

Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data

M. Jamieson, P. Gargalovic, C. Russ, 2022, American Journal of Cardiovascular Drugs.

Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database

C. Russ, M. Ferri, P. Hlavacek, 2022, Journal of Interventional Cardiac Electrophysiology.

Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants

T. Ingall, C. Russ, G. Lip, 2022, JAMA network open.

Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data

M. Jamieson, P. Gargalovic, C. Russ, 2022, American Journal of Cardiovascular Drugs.

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity

C. Russ, M. Ferri, B. Emir, 2022, Advances in Therapy.

Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.

J. Cappelleri, C. Russ, K. Fahrbach, 2022, Future cardiology.

Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs.

C. Russ, T. Alfred, S. Deitelzweig, 2022, The American journal of cardiology.

Warfarin Time in Therapeutic INR Range and Direct Oral Anticoagulant Adherence for Venous Thromboembolism Across the Spectrum of Weight and Body Mass Index: Findings from Veterans Health Administration

M. Turakhia, C. Russ, P. Hlavacek, 2023, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA

C. Russ, Jay Lin, S. Deitelzweig, 2020, Journal of medical economics.

Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants

C. Russ, O. Dina, Jay Lin, 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients

C. Russ, O. Dina, Jay Lin, 2019, Current medical research and opinion.

Efficacy and Safety of Pharmacotherapeutic Smoking Cessation Aids in Schizophrenia Spectrum Disorders: Subgroup Analysis of EAGLES.

N. Benowitz, R. West, D. Lawrence, 2020, Psychiatric services.

Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.

S. Rennard, R. West, J. Ebbert, 2015, JAMA.

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial

N. Benowitz, R. West, A. Krishen, 2016, The Lancet.

Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial

N. Benowitz, R. West, A. Krishen, 2019, Journal of General Internal Medicine.

Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations

K. Fagerström, S. Tonstad, P. Hajek, 2020, Current medical research and opinion.

The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data.

K. Fagerström, C. Yunis, C. Russ, 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population

C. Russ, M. Ferri, P. Hlavacek, 2019, Current medical research and opinion.

Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States

M. Turakhia, C. Russ, M. Ferri, 2021, Clinical cardiology.

Correction to: Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS Medicare population

A. Amin, C. Russ, A. Nadkarni, 2019, Journal of Thrombosis and Thrombolysis.

Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population

A. Amin, C. Russ, A. Nadkarni, 2019, Journal of Thrombosis and Thrombolysis.

Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database

C. Russ, M. Ferri, P. Hlavacek, 2022, Journal of Interventional Cardiac Electrophysiology.

Effects of Varenicline on Smoking Cessation in Adults With Stably Treated Current or Past Major Depression

C. Yunis, S. Dubrava, R. Anthenelli, 2013, Annals of Internal Medicine.

Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment.

S. Tonstad, P. Hajek, C. Russ, 2009, Addiction.

A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates

S. Rennard, J. Hughes, C. Russ, 2011, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active‐ and placebo‐controlled EAGLES trial

D. Lawrence, R. Anthenelli, A. Evins, 2019, Depression and anxiety.

Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial

N. Benowitz, R. West, A. Krishen, 2019, Journal of clinical psychopharmacology.

Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: Subgroup analysis of a randomized clinical trial.

R. West, A. Krishen, D. Lawrence, 2019, Journal of affective disorders.

Association of deferring a quit attempt with smoking cessation success: a secondary analysis.

J. Hughes, C. Russ, M. Messig, 2014, Journal of Substance Abuse Treatment.

Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: a cross-study analysis.

S. Rennard, J. Hughes, C. Russ, 2011, Addictive behaviors.

Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States

C. Russ, O. Dina, Jay Lin, 2020, Journal of drug assessment.

Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.

C. Russ, M. Ferri, P. Hlavacek, 2020, Thrombosis research.

Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors

N. Benowitz, R. West, A. Krishen, 2021, Addiction.

Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database

C. Russ, P. Hlavacek, J. Mardekian, 2020, Journal of managed care & specialty pharmacy.

A Real-World Evaluation of Primary Medication Nonadherence in Patients with Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the United States

C. Russ, M. DeKoven, V. Divino, 2023, American Journal of Cardiovascular Drugs.

Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs.

C. Russ, T. Alfred, S. Deitelzweig, 2021, The American journal of cardiology.

Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline

S. Tonstad, J. Hughes, C. Russ, 2010, Drug safety.

Effects of Varenicline on Smoking Cessation in Adults With Stably Treated Current or Past Major Depression

C. Yunis, S. Dubrava, R. Anthenelli, 2013, Annals of Internal Medicine.

Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database

C. Russ, M. Ferri, P. Hlavacek, 2022, PloS one.